Cargando…

Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience

BACKGROUND: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the inciden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taliansky, A., Furman, O., Gadot, M., Urban, D., Bar, J., Shapira-Frumer, R., Kaufman, B., Asher, N., Leibowitz-Amit, R., Itay, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550117/ https://www.ncbi.nlm.nih.gov/pubmed/34120259 http://dx.doi.org/10.1007/s00520-021-06331-5

Ejemplares similares

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
por: Dietz, Hilary, et al.
Publicado: (2021)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
por: Fontana, Flavia, et al.
Publicado: (2019)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
por: Bar-Hai, Neta, et al.
Publicado: (2023)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
por: Olbryt, Magdalena, et al.
Publicado: (2020)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma
por: Melin, Audrey, et al.
Publicado: (2022)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
por: de Azevedo, Ricardo A., et al.
Publicado: (2020)

Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
por: Crosby, Brendan J., et al.
Publicado: (2023)

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
por: Escandon, Julia, et al.
Publicado: (2017)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
por: Karlsson, Adam K, et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_igjcnf305t9gvi9qtsm55v4p1l